Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International    BAX

BAXTER INTERNATIONAL (BAX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL
04/19BAXTER INTERNATIONAL : Patent Issued for Integrated Water Testing Methods for Ul..
AQ
04/19BAXTER INTERNATIONAL : Patent Issued for Method of Operating an Infusion Pump wi..
AQ
04/12BAXTER INTERNATIONAL : Patent Issued for Dialysis Machine Having Auto-Connection..
AQ
04/12BAXTER INTERNATIONAL INC. : to Host Webcast of Annual Meeting of Stockholders
AQ
04/05BAXTER INTERNATIONAL : Patent Issued for Renal Therapy Machine and System Includ..
AQ
04/05BAXTER INTERNATIONAL : Patent Issued for Multi-State Alarm System for a Medical ..
AQ
04/04BAXTER INTERNATIONAL : to Host First Quarter 2018 Financial Results Conference C..
BU
04/03BAXTER INTERNATIONAL INC. : to Host Webcast of Annual Meeting of Shareholders
AQ
04/02BAXTER INTERNATIONAL INC. : to Host Webcast of Annual Meeting of Stockholders
BU
03/30NERVE REPAIR AND REGENERATION MARKET : Nerve Repair and Regeneration Market By A..
AQ
More news
News from SeekingAlpha
04/20Key events next week - healthcare 
04/02DIVIDEND GROWTH 50 : Not Perfect, But Yet Another 8% Raise 
03/28Why Should You Start Accumulating Baxter In 2018? 
03/08Baxter (BAX) Presents At Raymond James 39th Annual Institutional Investors Co.. 
03/02Key events next week - healthcare 
Financials ($)
Sales 2018 11 253 M
EBIT 2018 1 913 M
Net income 2018 1 406 M
Finance 2018 650 M
Yield 2018 1,02%
P/E ratio 2018 27,24
P/E ratio 2019 22,99
EV / Sales 2018 3,15x
EV / Sales 2019 2,96x
Capitalization 36 060 M
Chart BAXTER INTERNATIONAL
Duration : Period :
Baxter International Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Technical analysis trends BAXTER INTERNATIONAL
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 75,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Sumant Ramachandra Chief Science & Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL3.73%36 060
MEDTRONIC PLC-1.05%108 294
ZIMMER BIOMET HOLDINGS-7.81%22 415
TERUMO CORP10.59%21 605
HOYA CORPORATION-0.61%20 235
ALIGN TECHNOLOGY, INC.11.20%19 801